5. Peos JJ, et al. Intermittent Dieting: Theoretical Considerations for the Athlete. Sports (Basel). 2019; 7(1): 22.

6. Johanssen DL, et al. Metabolic slowing with massive weight loss despite preservation of fat-free mass. J Clin Endocrinol Metab. 2012; 97: 2489–2496.

7. Fothergill E, et al. Persistent metabolic adaptation 6 years after “The Biggest Loser” competition. Obesity 2016; 24(8): 1612–1619.

8. Ludwig DS, Ebbeling CB. The carbohydrate-insulin model of obesity: beyond “Calories In, Calories Out”. JAMA Intern Med 2018; 178: 1098–1103.

9. Samaha FF, et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 2003; 348: 2074–2081.

10. High Cholesterol Facts | cdc.gov 2022.

11. 국민건강영양조사 2020년

12. Caleyachetty R, et al. Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: A population-based cohort study. Lancet Diabetes Endocrinol. 2021; 9: 419–426.

13. Kashima, S, et al. Prevalence and characteristics of non-obese diabetes in Japanese men and women: The Yuport Medical Checkup Center Study. J. Diabetes 2015; 7: 523–530.

14. Yang HK, et al. Obesity, metabolic health, and mortality in adults: a nationwide

15. Chen GC, et al. Association between regional body fat and cardiovascular disease risk among postmenopausal women with normal body mass index. Eur Heart J. 2019; 40: 2849–2855.

16. Eckel N, et al. Metabolically healthy obesity and cardiovascular events: A systematic review and meta-analysis. Eur. J. Prev. Cardiol. 2016; 23: 956–966.

17. Ziyi Zhou, et al. Are people with metabolically healthy obesity really healthy? A prospective cohort study of 381,363 UK Biobank participants. Diabetologia. 2021; 64: 1963–1972.

Часть 2. Настоящая причина набора веса

18. Stunkard A, et al. An adoption study of human obesity. NEJM. 1986; 314: 193–198.

19. Bray GA. Contemporary diagnosis and management of obesity. Newtown, PA: Handbooks in Health Care, 1998.

20. McQuaid SE, et al. Downregulation of adipose tissue fatty acid trafficking in obesity: a driver for ectopic fat deposition? Diabetes. 2011; 60: 47–55.

21. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58: 773–795.

22. Lee SH, et al. Insulin Resistance: From Mechanisms to Therapeutic Strategies. Diabetes Metab J 2022; 46(1): 15–37.

23. Tabák AG, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009; 373: 2215–2221.

24. Pearson, T, et al. The Effects of Insulin Resistance on Individual Tissues: An Application of a Mathematical Model of Metabolism in Humans. Bull Math Biol 2016; 78: 1189–1217.

25. Chen Y, Lee Y, Tsao Y, et al Association between high-fasting insulin levels and metabolic syndrome in non-diabetic middle-aged and elderly populations: a community-based study in Taiwan. BMJ Open 2018; 8:e016554. Doi: 10.1136/bmjopen-2017-016554.

26. Sung, KC.C., Seo, MH.H., Rhee, EJ.J. et al. Elevated fasting insulin predicts the future incidence of metabolic syndrome: a 5-year follow-up study. Cardiovasc Diabetol 10, 108 (2011). https://doi.org/10.1186/1475-2840-10-108

27. Jeong J, Suh YJ. Association between Serum Uric Acid and Metabolic Syndrome in Koreans. J Korean Med Sci. 2019 Dec; 34(48): e307.

28. Tanabe A, Tatsumi F, Okauchi S, et al. Optimal cut-off value of alanine aminotransferase level to precisely estimate the presence of fatty liver in patients with poorly controlled type 2 diabetes. J Diabetes Investig 2016; 7: 645–646.

29. Arner P, et al. Human white adipose tissue: A highly dynamic metabolic organ. Journal of Internal Medicine. 2022; 291(5): 611–621.

30. Spalding KL, et al. Dynamics of fat cell turnover in humans. Nature. 2008; 453: 783–787.

31. Longo M. et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications Int J Mol Sci. 2019; 20(9): 2358.

32. Lloyd LJ, et al. Childhood obesity and adult cardiovascular disease risk: a systematic review. International Journal of Obesity. 2010; 34: 18–28.

33. Wrzosek M, et al. Early Onset of Obesity and Adult Onset of Obesity as Factors Affecting Patient Characteristics Prior to Bariatric Surgery. Obes Surg. 2018; 28(12): 3902–3909.

34. Wang X, et al. Adipose Tissue Aging and Metabolic Disorder, and the Impact of Nutritional Interventions. Nutrients. 2022; 14(15): 3134.

35. Ludwig J, et al. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55: 434–438.

36. Vos MB, et al. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J Med. 2008; 10: 160.

37. Maruhama Y, Macdonald I. Incorporation of orally administered glucose-U-14C and fructose-U-14C into the triglyceride of liver, plasma, and adipose tissue of rats. Metabolism. 1973; 22(9): 1205–1215.

38. Geidl-Flueck B, et al. Fructose and sucrose but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial. J. Hepatol. 2021; 75: 46–54.

39. Stanhope KL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Investig. 2009; 119: 1322–1334.

40. Lanaspa MA, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and independent fatty liver. J Biol Chem. 2012; 287(48): 40732–40744.

41. Ouyang X, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008;48(6): 993–999.

42. Maersk M, et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. Am J Clin Nutr. 2012; 95(2): 283–289.

43. Schwarz JM, et al. Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity. Gastroenterology. 2017; 153(3): 743–752.

44. Jensen T. et al. Fructose and Sugar: A Major Mediator of Nonalcoholic Fatty Liver Disease. J Hepatol. J Hepatol. 2018; 68(5): 1063–1075.

45. Wenting Wang, et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study. Scientific Reports. 2022; 12: 10 977.

46. Wei H, et al. Associations between sitting time and non-alcoholic fatty liver diseases in Chinese male workers: a cross-sectional study. BMJ Open. 2016; 6.

47. Ruohui Xu a, et al. Recent advances in lean NAFLD. Biomedicine & Pharmacotherapy. 153 (2022) 113331: 1–8.

48. Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73: 202–209.

49. Hart CL, et al. Effect of body mass index and alcohol consumption on liver